Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination for Patients with Newly Diagnosed Immune Thrombocytopenia: A Pilot "Total Therapy" Study

David Gomez-Almaguer, MD, Olga Cantu-Rodriguez, MD, Cesar Homero Gutierrez-Aguirre, MD, Jose Carlos Jaime-Perez, MD PhD, Luz C. Tarin-Arzaga, MD, Monica Sanchez Cardenas, MD, Rosa Elena Lozano-Morales, MD, Guillermo Sotomayor Duque, MD, Daniela Cárdenas-Araujo, MD, Andres Gomez-de Leon, MD, Paola Santana-Hernandez, Perla Rocío Colunga-Pedraza, MD

Blood (2016) 128 (22): 1369.

https://doi.org/10.1182/blood.V128.22.1369.1369

Published: 2016

Journal Articles

Low Dose Rituximab and Plasma Exchange As Frontline Therapy for Patients with Thrombotic Thrombocytopenic Purpura

Alberto Vazquez Mellado, MD, Olga Graciela Cantu-Rodriguez, MD, Myrna Pequeño-Luévano, MD, Laura Villarreal-Martínez, MD, José Carlos Jaime-Pérez, MD, Andres Gomez-De-Leon, MD, Oscar Gonzalez-Llano, MD PhD, Perla Colunga-Pedraza, MD, Guillermo Sotomayor-Duque, David Gomez-Almaguer, MD

Blood (2015) 126 (23): 2257.

https://doi.org/10.1182/blood.V126.23.2257.2257

Published: 2015

Journal Articles

Unmanipulated Peripheral Blood Stem Cells Can be Safely Used to Allograft Patients with Severe Aplastic Anemia; The Impact of ATG in Latin American Experience

Alberto Vazquez-Mellado, MD, Juan Ramon Navarro Cabrera, MD, Virginia Abello Polo, MD, Cesar Homero Gutierrez Aguirre, MD, Adriana Bustinza, MD, Enrique Pedraza Mesa, Jose Carlos Jaime Perez, Licet Villamizar Gómez, Samanta Becerra Galindo, Nancy Labastida Mercado, Guillermo J. Ruiz-Arguelles, MD FRCP (Glasg), MACP, David Gómez-Almaguer, MD

Blood (2014) 124 (21): 1255.

https://doi.org/10.1182/blood.V124.21.1255.1255

Published: 2014

Journal Articles

Autologus Hematopoietic Stem Cell Transplant in Type 1 Diabetes Mellitus in a Nonmyeloablative and Outpatient Setting

Olga Graciela Cantú-Rodríguez, MD, Fernando Lavalle-Gonzalez, MD, Miguel Angel Herrera-Rojas, MD, Cesar H Gutiérrez-Aguirre, MD, Consuelo Mancías-Guerra, MD, Jose Carlos Jaime-Pérez, MD, Oscar Gonzalez-Llano, MD, Alfonso Zapata-Garrido, MD, Jesus Zacarias Villarreal-Perez, MD, David Gomez-Almaguer, MD

Blood (2014) 124 (21): 1191.

https://doi.org/10.1182/blood.V124.21.1191.1191

Published: 2014

Journal Articles

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

David Gomez-Almaguer, MD, Miguel Angel Herrera-Rojas, MD, Andres Gomez-de Leon, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD, Guillermo J. Ruiz-Arguelles, MD, FRCP (Glasg), MACP, Jesus Hernandez-Reyes, MD

Blood (2013) 122 (21): 3544.

https://doi.org/10.1182/blood.V122.21.3544.3544

Published: 2013

Journal Articles

Prevalence Of FLT3 Mutations In Acute Myeloid Leukemia: A Multicenter Latin America Study

Jorge Cuervo-Sierra, MD, David Gómez-Almaguer, MD, Jose Carlos Jaime-Pérez, MD, Ramón Alejandro Martínez-Hernández, MD, Ricardo David García Sepúlveda, MD, Mónica Sánchez-Cárdenas, MD, Rocio Ortiz-López, MD, Gregorio Ignacio-Ibarra, MD, Gabriel Muciño-Hernández, MD, Rosa Maria Arana-Trejo, MD, Guillermo J. Ruiz-Arguelles, MD, FRCP (Glasg), MACP, Guillermo J. Ruiz-Delgado, MD, Julia Lutz-Prestno, MD, Angélica Jiménez-Mejía, MD, Gonzalo Vásquez-Palacio, Biol. Esp. Msc., Mauricio Camargo-Guerrero, MD

Blood (2013) 122 (21): 4979.

https://doi.org/10.1182/blood.V122.21.4979.4979

Published: 2013

Journal Articles

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

David Gomez-Almaguer, MD, Roxana Saldaña-Vázquez, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD

Blood (2013) 122 (21): 4034.

https://doi.org/10.1182/blood.V122.21.4034.4034

Published: 2013

Journal Articles

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias

David Gómez-Almaguer, Manuel Solano-Genesta, Luz Tarín-Arzaga, José Luis Herrera-Garza, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, José Carlos Jaime-Pérez

Blood (2010) 116 (23): 4783–4785.

https://doi.org/10.1182/blood-2010-06-291831

Published: 2010

Journal Articles

Alemtuzumab and Rituximab in the treatment of refractory autoimmune Cytopenias.

David Gomez-Almaguer, Manuel Solano-Genesta, MD, Olga Cantu-Rodriguez, MD, Cesar Homero Gutierrez-Aguilar, MD, Jose Carlos Jaime-Perez, MD, Luz Carmen Tarin-Arzaga, MD, Miguel Angel Gomez-Guijosa, MD

Blood (2009) 114 (22): 4458.

https://doi.org/10.1182/blood.V114.22.4458.4458

Published: 2009

Journal Articles

Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.

David Gomez-Almaguer, Guillermo Ruiz-Arguelles, Oscar Gonzalez-Llano, Olga G. Cantu, Cesar H. Gutierrez, Jose Carlos Jaime-Perez, Luz Tarin-Arzaga, Sergio Giralt

Blood (2006) 108 (11): 5294.

https://doi.org/10.1182/blood.V108.11.5294.5294

Published: 2006

NARROW

Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination for Patients with Newly Diagnosed Immune Thrombocytopenia: A Pilot "Total Therapy" Study

Low Dose Rituximab and Plasma Exchange As Frontline Therapy for Patients with Thrombotic Thrombocytopenic Purpura

Unmanipulated Peripheral Blood Stem Cells Can be Safely Used to Allograft Patients with Severe Aplastic Anemia; The Impact of ATG in Latin American Experience

Autologus Hematopoietic Stem Cell Transplant in Type 1 Diabetes Mellitus in a Nonmyeloablative and Outpatient Setting

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

Prevalence Of FLT3 Mutations In Acute Myeloid Leukemia: A Multicenter Latin America Study

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias

Alemtuzumab and Rituximab in the treatment of refractory autoimmune Cytopenias.

Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only